Actinium Pharmaceuticals, Inc.

• Booth: 230

Older patients with active, rel/ref AML can be transplanted.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for our ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. Our lead product candidate, I-131 apamistamab [Iomab-B] is being studied in the ongoing pivotal Phase 3 'Study of Iomab-B in Elderly Relapsed/Refractory Acute Myeloid Leukemia' (SIERRA) trial for BMT conditioning. I-131 apamistamab will also be studied as a targeted conditioning agent in a HIV-lymphoma stem cell gene therapy at UC-Davis and is expected to be studied with a CAR-T therapy. In addition, we are advancing our anti-CD33 (Ac-225 lintuzumab) program, including a trial in combination with CLAG-M (at the Medical College of Wisconsin) and one with the BCL-2 inhibitor venetoclax.

Brands: I-131 apamistamab [Iomab-B; I-131 BC8] is the investigational drug candidate in SIERRA: the only Phase 3 trial offering allogeneic HCT to patients with active, relapsed/refractory AML.